FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

NT OF DEVICE OUT ON THE OF

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden

Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			the Investment Company Act of 1						
1. Name and Address of Reporting Person* <u>Fussell Stephen R</u>	2. Date of Event Requiring Statement (Month/Day/Year) 06/01/2005		3. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]						
(Last) (First) (Middle) 100 ABBOTT PARK ROAD			Relationship of Reporting Pers (Check all applicable) Director Officer (give title	10% Owne	er (N	If Amendment, Date of Original Filed (Month/Day/Year) Individual or Joint/Group Filing (Check			
(Street) ABBOTT PARK IL 60064-6400	-		Senior Vice President			Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)									
	Table I - No		ive Securities Beneficial	1					
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ((Instr. 5)	cṫ (D) (In:	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common shares without par value			31,972	D					
Common shares without par value			1,084 ⁽¹⁾	I	pro	ofit sharing trus	sharing trust		
			e Securities Beneficially ints, options, convertible		s)				
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of Secur Underlying Derivative Securi		4. Conversion	se Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	ive or Indirect			
Option (right to buy) ⁽²⁾	02/14/2000	02/13/2007	Common shares	2,274	27.4328	3 D			
Option (right to buy) ⁽²⁾	02/13/2001	02/12/2008	Common shares	14,258	34.7727	7 D			
Option (right to buy) ⁽²⁾	03/29/1999	12/30/2006	Common shares	163	41.9151	l D			
Option (right to buy) ⁽²⁾	03/29/1999	02/13/2007	Common shares	620	41.9151	l D			
Option (right to buy) ⁽²⁾	02/12/2002	02/11/2009	Common shares	31,920	42.4978	B D			
Option (right to buy) ⁽²⁾	09/20/1999	12/30/2006	Common shares	875	45.7683	3 D			
Option (right to buy) ⁽²⁾	09/20/1999	02/13/2007	Common shares	4,293	45.7683	3 D			
Option (right to buy) ⁽²⁾	02/11/2003	02/10/2010	Common shares	35,835	32.6111	l D			
Option (right to buy) ⁽²⁾	03/22/2001	12/30/2006	Common shares	480	42.4226	5 D			
Option (right to buy) ⁽²⁾	03/22/2001	02/13/2007	Common shares	1,516	42.4226	5 D			
Option (right to buy) ⁽²⁾	02/09/2004	02/08/2011	Common shares	53,202	45.4488	3 D			
Option (right to buy) ⁽²⁾	02/15/2005	02/14/2012	Common shares	42,561	53.625	D			
Option (right to buy) ⁽²⁾	02/14/2004	02/13/2013	Common shares	1	33.2314	4 D			
Option (right to buy) ⁽²⁾	02/14/2005	02/13/2013	Common shares	35,467	33.2314	4 D			
Option (right to buy) ⁽²⁾	02/14/2006	02/13/2013	Common shares	17,734	33.2314	4 D			
Option (right to buy) ⁽²⁾	02/20/2005	02/19/2014	Common shares	8,867	41.0317	7 D			
Option (right to buy) ⁽²⁾	02/20/2006	02/19/2014	Common shares	8,867	41.0317	7 D			
Option (right to buy) ⁽²⁾	02/20/2007	02/19/2014	Common shares	8,866	41.0317	7 D			
Option (right to buy) ⁽²⁾	12/03/2004	02/13/2007	Common shares	915	41.01	D			
Option (right to buy) ⁽²⁾	12/03/2004	12/30/2006	Common shares	3,800	41.01	D			
Option (right to buy) ⁽²⁾	06/03/2005	02/10/2010	Common shares	5,724	43.25	D			
Option (right to buy) ⁽²⁾	06/03/2005	12/30/2006	Common shares	2,845	43.25	D			

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)				
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)					
Option (right to buy) ⁽³⁾	02/18/2006	02/17/2015	Common shares	9,667	46.34	D					
Option (right to buy) ⁽³⁾	02/18/2007	02/17/2015	Common shares	9,667	46.34	D					
Option (right to buy) ⁽³⁾	02/18/2008	02/17/2015	Common shares	9,666	46.34	D					

Explanation of Responses:

- $1. \ Balance \ in \ the \ Abbott \ Laboratories \ Stock \ Retirement \ Trust \ as \ of \ June \ 1, 2005.$
- 2. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3.
- 3. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.

John A. Berry, by power of attorney for Stephen R. Fussell

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned constitutes and appoints LAURA J. SCHUMACHER, JOHN A. BERRY and DEBORAH K. KOENEN, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Dated: May 27, 2005

/s/ Stephen R. Fussell
Signature of Reporting Person

Stephen R. Fussell
Senior Vice President

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064-6400